Allarity Therapeutics (ALLR)
Develops stenoparib with DRP®-guided patient selection for advanced recurrent ovarian cancer.
$1.05
vs last close−0.06 (−5.41%)
Something off on this page? Send us feedback.
Next report
Nov 13, 26
estimated · in 51 days
EPS estimate
−$0.25
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Apr '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$4.73−$0.25−$0.15−$0.19−$0.19−$0.17−$0.21Pending
Estimate−$8.10—−$0.21−$0.23−$0.22−$0.22−$0.25−$0.25
Surprise+41.6%—+28.6%+17.4%+13.6%+22.7%+16.0%—
RevenueReportedEstimate
Apr '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$6.0K———$320.0K$25.0K—Pending
Estimate————$320.0K$25.0K——
Surprise————0.0%0.0%——
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.24 | — | — |
| Sep 2027 | −$0.22 | — | — |
| Jun 2027 | −$0.22 | — | — |
| Mar 2027 | −$0.25 | — | — |
| Dec 2026 | −$0.25 | — | — |
| Nov 2026 | −$0.25 | — | — |
| Aug 2026 | −$0.25 | −$0.21 | +16.0% |
| May 2026 | −$0.22 | −$0.17 | +22.7% |
| Mar 2026 | −$0.22 | −$0.19 | +13.6% |
| Nov 2025 | −$0.23 | −$0.19 | +17.4% |
| Aug 2025 | |||
| May 2025 | |||
| Apr 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Oct 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Nov 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Dec 2019 | |||
| Sep 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.24 | — | — | $25.0K | — | — | — |
| Sep 2027 | −$0.22 | — | — | $0 | — | — | — |
| Jun 2027 | −$0.22 | — | — | $0 | — | — | — |
| Mar 2027 | −$0.25 | — | — | $25.0K | — | — | — |
| Dec 2026 | −$0.25 | — | — | $25.0K | — | — | — |
| Nov 13, 2026 | −$0.25 | — | — | $0 | — | — | — |
| Aug 14, 2026 | −$0.25 | −$0.21 | +16.0% | — | — | — | +0.7% |
| May 15, 2026 | −$0.22 | −$0.17 | +22.7% | $25.0K | $25.0K | 0.0% | −10.6% |
| Mar 31, 2026 | −$0.22 | −$0.19 | +13.6% | $320.0K | $320.0K | 0.0% | +3.7% |
| Nov 14, 2025 | −$0.23 | −$0.19 | +17.4% | — | — | — | −0.8% |
| Aug 15, 2025 | |||||||
| May 9, 2025 | |||||||
| Apr 4, 2025 | |||||||
| Nov 14, 2024 | |||||||
| Aug 5, 2024 | |||||||
| May 14, 2024 | |||||||
| Mar 8, 2024 | |||||||
| Nov 14, 2023 | |||||||
| Aug 14, 2023 | |||||||
| May 11, 2023 | |||||||
| Mar 13, 2023 | |||||||
| Nov 14, 2022 | |||||||
| Oct 7, 2022 | |||||||
| Aug 21, 2022 | |||||||
| May 17, 2022 | |||||||
| Nov 23, 2021 | |||||||
| Jun 30, 2021 | |||||||
| Mar 31, 2021 | |||||||
| Dec 31, 2020 | |||||||
| Sep 30, 2020 | |||||||
| Dec 31, 2019 | |||||||
| Sep 30, 2015 |